| Popis: |
Paul Y Takahashi,1 Euijung Ryu,2 James R Cerhan,3 Suzette J Bielinski,3 Janet E Olson3 1Division of Community Internal Medicine, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA; 2Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA; 3Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USACorrespondence: Paul Y TakahashiDivision of Community Internal Medicine, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USATel +1-507-284-2511Fax +1-507-266-2297Email Takahashi.paul@mayo.edu We appreciate the thoughts of Dr. Roman and his comments. We understand that the number of identified pharmacogenomic genes continues to increase with time, and the clinical utility also increases with time and expert opinion. We chose theseselected pharmacogenes because of their strong clinical practice recommendations and the data available at the time of the gene selection.1 Due largely to the efforts associated with other initiatives within the RIGHT study, our clinical practice set upspecific electronic medical record best practice alerts for these pharmacogenes, and it was believed that there was the potential for change in clinical care for patients with extreme phenotypes.2 We did not design the study to specifically look at allpharmacogenomic genes. View the original paper by Takahashi and colleagues This is in response to the Letter to the Editor |
